SCHEDULE: Vanguard Reports 0% Stake in Adaptive Biotechnologies
Beneficial Ownership Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Adaptive Biotechnologies Corp. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 6 to Schedule 13G for Adaptive Biotechnologies Corp. common stock.
- The filing reports 0% beneficial ownership of Adaptive Biotechnologies Corp. common stock by The Vanguard Group.
- This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately on a disaggregated basis.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event for Adaptive Biotechnologies Corp., as it reflects an internal organizational change within The Vanguard Group rather than a change in investment thesis or a divestment decision.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional investors like The Vanguard Group frequently adjust their reporting structures or reallocate holdings across various funds and subsidiaries. This specific filing reflects an internal organizational change within Vanguard rather than a strategic investment decision regarding Adaptive Biotechnologies Corp. itself, which is a common occurrence for large asset managers.
Stakeholder Impact
- Shareholders of Adaptive Biotechnologies Corp. should note that this filing indicates a change in how Vanguard's holdings are reported, not necessarily a complete divestment by all Vanguard-managed funds. The aggregate beneficial ownership reported by The Vanguard Group itself is now 0% due to disaggregation.
Key Dates
| Date | Description |
|---|---|
| 2026-01-12 | The Vanguard Group, Inc. underwent an internal realignment, leading to disaggregated beneficial ownership reporting. |
| 2026-03-13 | Date of event requiring the filing of this Schedule 13G amendment. |
| 2026-03-26 | Date the Schedule 13G amendment was signed by The Vanguard Group. |
Keywords
Adaptive Biotechnologies, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Ownership, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.